These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

430 related items for PubMed ID: 12079522

  • 21. Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins.
    Taniguchi K, Kohno K, Kawanami K, Wada M, Kanematsu T, Kuwano M.
    Cancer Res; 1996 May 15; 56(10):2348-54. PubMed ID: 8625310
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Comparison of stepwise and pulse induced cisplatin-resistant ovarian cancer cell sublines].
    Cheng G, Li Y, Tian F.
    Zhonghua Zhong Liu Za Zhi; 2001 Jul 15; 23(4):305-8. PubMed ID: 11783113
    [Abstract] [Full Text] [Related]

  • 25. Establishment and gene analysis of a cisplatin-resistant cell line, Sa-3R, derived from oral squamous cell carcinoma.
    Nakatani K, Nakamura M, Uzawa K, Wada T, Seki N, Tanzawa H, Fujita S.
    Oncol Rep; 2005 Apr 15; 13(4):709-14. PubMed ID: 15756446
    [Abstract] [Full Text] [Related]

  • 26. BIRICODAR (VX-710; Incel): an effective chemosensitizer in neuroblastoma.
    Yanagisawa T, Newman A, Coley H, Renshaw J, Pinkerton CR, Pritchard-Jones K.
    Br J Cancer; 1999 Jun 15; 80(8):1190-6. PubMed ID: 10376971
    [Abstract] [Full Text] [Related]

  • 27. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines.
    Hasegawa S, Abe T, Naito S, Kotoh S, Kumazawa J, Hipfner DR, Deeley RG, Cole SP, Kuwano M.
    Br J Cancer; 1995 May 15; 71(5):907-13. PubMed ID: 7734314
    [Abstract] [Full Text] [Related]

  • 28. CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein.
    Jansen WJ, Hulscher TM, van Ark-Otte J, Giaccone G, Pinedo HM, Boven E.
    Br J Cancer; 1998 May 15; 77(3):359-65. PubMed ID: 9472629
    [Abstract] [Full Text] [Related]

  • 29. 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.
    Saijo N, Nishio K, Kubota N, Kanzawa F, Shinkai T, Karato A, Sasaki Y, Eguchi K, Tamura T, Ohe Y.
    Cancer Chemother Pharmacol; 1994 May 15; 34 Suppl():S112-7. PubMed ID: 8070019
    [Abstract] [Full Text] [Related]

  • 30. Mechanisms of taxotere-related drug resistance in pancreatic carcinoma.
    Liu B, Staren ED, Iwamura T, Appert HE, Howard JM.
    J Surg Res; 2001 Aug 15; 99(2):179-86. PubMed ID: 11469885
    [Abstract] [Full Text] [Related]

  • 31. Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line.
    Violini S, D'Ascenzo S, Bagnoli M, Millimaggi D, Miotti S, Canevari S, Pavan A, Dolo V.
    J Exp Clin Cancer Res; 2004 Mar 15; 23(1):83-91. PubMed ID: 15149155
    [Abstract] [Full Text] [Related]

  • 32. Establishment and characterization of 6-[[2-(Dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride (TAS-103)-resistant cell lines.
    Aoyagi Y, Kobunai T, Utsugi T, Wierzba K, Yamada Y.
    Jpn J Cancer Res; 2000 May 15; 91(5):543-50. PubMed ID: 10835500
    [Abstract] [Full Text] [Related]

  • 33. Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line.
    Wen J, Zheng B, Hu Y, Zhang X, Yang H, Luo KJ, Zhang X, Li YF, Fu JH.
    Oncol Rep; 2009 Jul 15; 22(1):65-71. PubMed ID: 19513506
    [Abstract] [Full Text] [Related]

  • 34. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
    Koshiyama M, Fujii H, Kinezaki M, Morita Y, Nanno H, Yoshida M.
    Anticancer Res; 2001 Jul 15; 21(4B):2925-32. PubMed ID: 11712788
    [Abstract] [Full Text] [Related]

  • 35. Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line.
    Naito S, Hasegawa S, Yokomizo A, Koga H, Kotoh S, Kuwano M, Kumazawa J.
    Jpn J Cancer Res; 1995 Nov 15; 86(11):1112-8. PubMed ID: 8567404
    [Abstract] [Full Text] [Related]

  • 36. MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity.
    Sakai A, Kasahara K, Ohmori T, Kimura H, Sone T, Fujimura M, Nakao S.
    J Thorac Oncol; 2012 Sep 15; 7(9):1337-44. PubMed ID: 22722827
    [Abstract] [Full Text] [Related]

  • 37. Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma.
    Li L, Luan Y, Wang G, Tang B, Li D, Zhang W, Li X, Zhao J, Ding H, Reed E, Li QQ.
    Int J Mol Med; 2004 Aug 15; 14(2):257-64. PubMed ID: 15254775
    [Abstract] [Full Text] [Related]

  • 38. The association between chemosensitivity and Pgp, GST-π and Topo II expression in gastric cancer.
    Geng M, Wang L, Chen X, Cao R, Li P.
    Diagn Pathol; 2013 Dec 10; 8():198. PubMed ID: 24326092
    [Abstract] [Full Text] [Related]

  • 39. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
    Beketic-Oreskovic L, Durán GE, Chen KG, Dumontet C, Sikic BI.
    J Natl Cancer Inst; 1995 Nov 01; 87(21):1593-602. PubMed ID: 7563202
    [Abstract] [Full Text] [Related]

  • 40. Determinants of cisplatin and irinotecan activities in human lung adenocarcinoma cells: evidence of cisplatin accumulation and topoisomerase I activity.
    Matsumura T, Takigawa N, Kiura K, Shibayama T, Chikamori M, Tabata M, Ueoka H, Tanimoto M.
    In Vivo; 2005 Nov 01; 19(4):717-21. PubMed ID: 15999539
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.